ArticleBMJ case reports2022

When one plus one means more than two: the blockade of both IL-4 and IL-13 inflammatory pathways with dupilumab in a case of severe refractory T2-high asthma.

Carmelo Sofia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.